SI Money Map · Client
GSK (FKA GLAXOSMITHKLINE INC.) and SI policy
GSK (FKA GLAXOSMITHKLINE INC.) is the client on 7 federal lobbying reports that name SI issues, Q1 2025 to Q3 2026, disclosing $8.9M by the amount rule: $4.8M in 2025 and $4.1M in 2026 so far. It filed 7 reports for itself. Rank 57 of 1,245 clients. Read from LDA.gov, Nov 17, 2026. Amounts are filing totals for all issues on each filing.
Over time
Quarter by quarter
Q1 2025 to Q3 2026. Q3 2026 reports were due Oct 20, 2026.
| Quarter | Filings | In-house | Outside firms | Counted |
|---|---|---|---|---|
| Q3 2026 | 1 | $1,530,000 | none | $1,530,000 |
| Q2 2026 | 1 | $890,000 | none | $890,000 |
| Q1 2026 | 1 | $1,640,000 | none | $1,640,000 |
| Q4 2025 | 1 | $810,000 | none | $810,000 |
| Q3 2025 | 1 | $1,700,000 | none | $1,700,000 |
| Q2 2025 | 1 | $1,510,000 | none | $1,510,000 |
| Q1 2025 | 1 | $800,000 | none | $800,000 |
The filings
Every SI filing for GSK (FKA GLAXOSMITHKLINE INC.)
Each LD-2 report with at least one issue line that names SI, newest first, with the link to the filing on LDA.gov. "SI lines" shows how many of the filing's issue lines name SI.
| Quarter | Filed by | Amount | SI lines | Issue codes and bills | Source |
|---|---|---|---|---|---|
Q3 2026Q3, posted Oct 20, 2026 | GSK (FKA GLAXOSMITHKLINE INC.)In-house | $1,530,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1492, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 3521, H.R. 4317 ... | |
Q2 2026Q2, posted Jul 16, 2026 | GSK (FKA GLAXOSMITHKLINE INC.)In-house | $890,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 3521 ... | |
Q1 2026Q1, posted Apr 20, 2026 | GSK (FKA GLAXOSMITHKLINE INC.)In-house | $1,640,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269 ... | |
Q4 2025Q4, posted Jan 20, 2026 | GSK (FKA GLAXOSMITHKLINE INC.)In-house | $810,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269 ... | |
Q3 2025Q3, posted Oct 20, 2025 | GSK (FKA GLAXOSMITHKLINE INC.)In-house | $1,700,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 4132 ... | |
Q2 2025Q2, posted Jul 21, 2025 | GSK (FKA GLAXOSMITHKLINE INC.)In-house | $1,510,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 4132 ... | |
Q1 20251A, posted May 6, 2025 | GSK (FKA GLAXOSMITHKLINE INC.)In-house | $800,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1262, H.R. 1492, H.R. 1574, H.R. 198, H.R. 2214, H.R. 890, H.R. 946, S. 1040 ... |
In their own words
What the filings say
The SI issue lines, quoted as filed: newest first, repeats left out, long lines cut short. The words are the filers'; the filings are public records.
- Names as filed
- GSK (FKA GLAXOSMITHKLINE INC.)
- Issue codes
- Copyright/Patent/Trademark (7), Health Issues (7)
- Bills named
- S. 2658 (9), S. 1040 (7), S. 1041 (7), S. 1095 (7), S. 1096 (7), S. 43 (7), H.R. 1492 (7), H.R. 2214 (7), H.R. 946 (7), S. 832 (7), H.R. 890 (6), S. 1097 (6)
"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent ..."
Copyright/Patent/Trademark, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. ..."
Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1414: Expedited Access to Biosimilars Act S. 1954: ..."
Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing"S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and ..."
Copyright/Patent/Trademark, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - ..."
Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 882: Patients Before Middlemen Act, and other legislation ..."
Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing"S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864, HELP Copays Act - A bill to amend title XXVII of the Public Health Service Act to apply financial assistance ..."
Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing"S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a ..."
Health Issues, filed by GSK (FKA GLAXOSMITHKLINE INC.). The filing
Embed
Put this card on any page
A plain image that links back here, with its source printed on it. Free under CC BY 4.0. Filings, not influence. The SI Money Map shows what federal disclosure filings report: who paid for lobbying, which issues and bills the filings name, and what super PACs raised and spent. It does not show influence, intent or results, and it takes no side.
<a href="https://tsio.si/money-map/gsk-fka-glaxosmithkline-inc/"><img src="https://tsio.si/money-map/gsk-fka-glaxosmithkline-inc/card.svg" width="480" height="240" alt="The SI Money Map: GSK (FKA GLAXOSMITHKLINE INC.), $8.9M reported on SI lobbying filings"></a>